Search

Your search keyword '"Sonidegib"' showing total 16 results
Start Over Descriptor "Sonidegib" Database Gale General OneFile
16 results on '"Sonidegib"'

1. Department of Onco-Hematology Researchers Update Current Data on Basal Cell Cancer (A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature)

Subjects
Elderly patients -- Care and treatment, Physical fitness, Basal cell carcinoma -- Care and treatment, Cancer research, Biochemistry, Vismodegib, Sonidegib, Health
Abstract

2020 DEC 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on basal cell cancer. According to news reporting [...]

Published
2020

2. Sun Pharma to present key clinical data from dermatology portfolio

Subjects
Aminolevulinic acid, Tildrakizumab, Skin cancer, Sonidegib, Squamous cell carcinoma, Pharmaceuticals and cosmetics industries, American Academy of Dermatology
Abstract

Byline: Our Bureau Sun Pharma will present 25 data abstracts from its diverse dermatology portfolio at the upcoming American Academy of Dermatology (AAD) Virtual meeting experience 2020. The data presentation [...]

Published
2020

3. Studies from QIMR Berghofer Medical Research Institute Describe New Findings in Smoothened Receptor Antagonists (Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic ...)

Subjects
Clinical trials, Physical fitness, Medical research, Vismodegib, Sonidegib, Brain tumors, Adults, Obesity, Gliomas, Anopheles, Medulloblastoma, Tumors, Editors, Health
Abstract

2019 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Smoothened Receptor Antagonists have [...]

Published
2019

4. Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

Subjects
Basal cell carcinoma -- Care and treatment, Physical fitness, Clinical trials, Vismodegib, Sonidegib, Obesity, Cancer treatment, Skin, Cancer, Skin cancer, Carcinoma, Editors, Health
Abstract

2019 MAY 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Senhwa Biosciences, Inc. (TPEx: 6492) announced that the clinical trial of Silmitasertib [...]

Published
2019

5. Senhwa Biosciences begins patient enrollment in clinical trial of Silmitasertib to treat basal cell carcinoma

Subjects
Clinical trials, Vismodegib, Basal cell carcinoma, Sonidegib, Cancer treatment, Skin, Cancer, Skin cancer, Carcinoma, Pharmaceuticals and cosmetics industries
Abstract

Senhwa Biosciences, Inc announced that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell Carcinoma (BCC) has enrolled its first patient at Texas Oncology, Texas, USA. The [...]

Published
2019

6. Indian scientists identify new potential drug treatments for Covid-19

Subjects
Coronaviruses, Baloxavir marboxil, Olaparib, Regorafenib, Sonidegib, Drug approval, COVID-19 -- Care and treatment, Scientists, Business, international, Law
Abstract

Indian scientists have identified drugs and possible cocktails that can target vital proteins of the novel coronavirus, and may potentially help treat COVID-19. Using a virtual screening of the DrugBank [...]

Published
2020

7. Treatments Beyond Localized Skin Surgery for BCC, SCC, and Localized Melanoma

Author

Zachary, Christopher B.

Subjects
United States. Food and Drug Administration, Cancer treatment, Embryonic development, Skin cancer -- Care and treatment, Vismodegib, Skin, Sonidegib, Squamous cell carcinoma -- Care and treatment, Melanoma -- Care and treatment, Drug approval, Carcinoma, Basal cell carcinoma, Novels, Health, Health care industry
Abstract

Standard treatment for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and localized melanoma usually includes skin surgery. Several novel treatments that are alternatives to surgery are reviewed briefly here. [...]

Published
2019

8. Cancer API Market SWOT Analysis, Key Players, Analysis and Forecasts Till 2023

Subjects
Brigatinib -- Market research, Enasidenib -- Market research, Osimertinib -- Forecasts and trends -- Reports, Ceritinib -- Forecasts and trends -- Reports, Valsartan -- Forecasts and trends -- Reports, Cobimetinib -- Reports -- Forecasts and trends, Cancer -- Forecasts and trends -- Reports, Market research -- Reports -- Forecasts and trends, Cancer research -- Reports -- Forecasts and trends, Acalabrutinib -- Market research, Ruxolitinib -- Market research, Lenvatinib -- Forecasts and trends -- Reports, Alectinib -- Forecasts and trends -- Reports, Neratinib -- Market research, Copanlisib -- Market research, Palbociclib -- Reports -- Forecasts and trends, Idelalisib -- Forecasts and trends -- Reports, Olaparib -- Reports -- Forecasts and trends, Abemaciclib -- Market research, Antineoplastic agents -- Market research, Afatinib, Niraparib, Regorafenib, Crizotinib, Lapatinib, Cabozantinib, Gefitinib, Dasatinib, Ponatinib, Axitinib, Ibrutinib, Bosutinib, Rucaparib, Sonidegib, Sorafenib, Vemurafenib, Dabrafenib, Ribociclib, Vismodegib, Sunitinib, Erlotinib, Marketing research, Market trend/market analysis, General interest
Abstract

New Delhi, April 10 -- Market Research Future added new report of 'Cancer API Market Research Report'- It contains Company information, geographical Segmentation, in-depth Table of Content, and List of [...]

Published
2020

9. EMA|116423|2018 Public summary of opinion on orphan designation Patidegib for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)

Subjects
Skin cancer -- Care and treatment, Carcinoma -- Care and treatment, Sonidegib, Orphans, Skin, Cancer, Tumors, Business, international, European Union
Abstract

Amsterdam: European Medicines Agency has issued the following document: On 21 March 2018, orphan designation (EU/3/18/1998) was granted by the European Commission to Blue-Reg Europe, France, for patidegib for the [...]

Published
2019

10. Senhwa Biosciences Silmitasertib|Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

Subjects
Clinical trials, Cancer treatment, Vismodegib, Basal cell carcinoma -- Care and treatment, Sonidegib, Skin, Cancer, Skin cancer, Carcinoma, General interest, News, opinion and commentary
Abstract

TAIPEI: Senhwa Biosciences, Inc. has issued the following news release: Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell [...]

Published
2019

11. Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

Subjects
Clinical trials, Cancer treatment, Vismodegib, Basal cell carcinoma -- Care and treatment, Sonidegib, Skin, Cancer, Skin cancer, Carcinoma, Business, News, opinion and commentary
Abstract

TAIPEI, Taiwan and SAN DIEGO, April 17, 2019 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell [...]

Published
2019

13. Researchers Submit Patent Application, 'Par-4 Agonists For The Treatment Of Cancer', for Approval (USPTO 20200046721)

Subjects
Cipla Ltd. -- Intellectual property, Cabazitaxel, Ixazomib, Ceritinib, Ionizing radiation, Cobimetinib, Ruxolitinib, Siltuximab, Alectinib, BCR-ABL tyrosine kinase inhibitors, Ramucirumab, Trifluridine, Olaparib, Nivolumab, Carboplatin, Obinutuzumab, Antibacterial agents, Cancer genetics -- Genetic aspects, Osimertinib, Cancer -- Genetic aspects, Monoclonal antibodies, Pembrolizumab, Belinostat, Decitabine, Palbociclib, Idelalisib, Blinatumomab, Bevacizumab, Pharmaceutical industry -- Intellectual property, Antineoplastic agents, Afatinib, Cancer treatment, Anopheles, Temsirolimus, Cabozantinib, Fulvestrant, Clofarabine, Pertuzumab, Dasatinib, Nelarabine, Ixabepilone, Axitinib, Vincristine, Ibrutinib, Editors, Sonidegib, Lenvatinib, Nilotinib, Tositumomab, Abiraterone, Dabrafenib, Pemetrexed, Vandetanib, Cetuximab, Carfilzomib, Romidepsin, Atezolizumab, Ipilimumab, Vismodegib, Trabectedin, Elotuzumab, Pralatrexate, Enzalutamide, Sunitinib, Regorafenib, Crizotinib, Necitumumab, Lapatinib, Degarelix, Public health, Dinutuximab, Everolimus, Vorinostat, Ponatinib, Bosutinib, Public health movements, Panitumumab, Brentuximab vedotin, Ofatumumab, Sorafenib, Bendamustine, Ibritumomab tiuxetan, Trametinib, Denosumab, Vemurafenib, Pazopanib, Panobinostat, Daratumumab, Biotechnology industry, Health, Science and technology
Abstract

2020 MAR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors [...]

Published
2020

14. Reports from University Children's Hospital of Zurich Advance Knowledge in Medulloblastoma (Crosstalk between SHH and FGFR Signaling Pathways Controls Tissue Invasion in Medulloblastoma)

Subjects
Fibroblast growth factors, Sonidegib, Medulloblastoma -- Development and progression, Gliomas, Tumors, Editors, Health
Abstract

2020 FEB 3 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Researchers detail new data in Oncology - Medulloblastoma. According to news reporting from Zurich, [...]

Published
2020

15. Patent Application Titled 'Uses Of Bcl-2 Antagonists For Treating Cancer And Diagnostics Related Thereto' Published Online (USPTO 20190328729)

Subjects
Cabazitaxel, Ixazomib, Ceritinib, Cobimetinib, Ruxolitinib -- Intellectual property, Acalabrutinib -- Intellectual property, Romiplostim -- Intellectual property, Siltuximab, Glucarpidase, Alectinib, Aminolevulinic acid -- Intellectual property, Midostaurin -- Intellectual property, BCR-ABL tyrosine kinase inhibitors, Ramucirumab, Trifluridine -- Intellectual property, Olaparib, Nivolumab, Carboplatin -- Intellectual property, Obinutuzumab, Lanreotide, Methylnaltrexone, Brigatinib -- Intellectual property, Rasburicase -- Intellectual property, Pamidronate -- Intellectual property, Axicabtagene ciloleucel -- Intellectual property, Enasidenib -- Intellectual property, Osimertinib, Palifermin -- Intellectual property, Cancer, Monoclonal antibodies, Pembrolizumab, Inotuzumab ozogamicin -- Intellectual property, Belinostat, Neratinib -- Intellectual property, Zoledronic acid, Decitabine, Copanlisib -- Intellectual property, Durvalumab -- Intellectual property, Palbociclib, Idelalisib, Blinatumomab, Bevacizumab -- Intellectual property, Antiemetics -- Intellectual property, Plerixafor, Abemaciclib -- Intellectual property, Eltrombopag -- Intellectual property, Talimogene laherparepvec, Antineoplastic agents -- Intellectual property, Afatinib, Temsirolimus, Cabozantinib, Fulvestrant, Pertuzumab, Dasatinib, Nelarabine, Axitinib, Ibrutinib, Sonidegib, Nilotinib, Abiraterone, Dabrafenib, Pemetrexed, Pomalidomide, Carfilzomib, Olaratumab, Enzalutamide, Sunitinib, Niraparib, Crizotinib, Necitumumab, Lapatinib, Dinutuximab, Ponatinib, Bosutinib, Rucaparib, Ofatumumab, Sorafenib, Bendamustine, Trametinib, Vemurafenib, Tumors, Ribociclib, Aflibercept, Panobinostat, Cancer treatment, Anopheles, Clofarabine, Ixabepilone, Vincristine, Editors, Lenvatinib, Rolapitant, Vandetanib, Aprepitant, Cetuximab, Atezolizumab, Romidepsin, Ipilimumab, Venetoclax, Trabectedin, Vismodegib, Elotuzumab, Pralatrexate, Regorafenib, Degarelix, Everolimus, Vorinostat, Avelumab, Palonosetron, Panitumumab, Brentuximab vedotin, Ibritumomab tiuxetan, Denosumab, Pazopanib, Daratumumab, Business, Health, Health care industry
Abstract

2019 NOV 19 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results